Preoperative markers for the prediction of high-risk features in endometrial cancer

doi:10.5306/wjco.v11.i6.378

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4940)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

202

WORD

109

HTML

2617

Figures (1-2)

316

Tables (1-4)

138

Sum=3382

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

654

Download

904

Sum=1558

Jun 24, 2020 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Clin Oncol. Jun 24, 2020; 11(6): 378-388
Published online Jun 24, 2020. doi: 10.5306/wjco.v11.i6.378

Open in New Tab Full Size Figure Download Figure

Figure 1 Receiver operating characteristic curve of serum cancer antigen 125 and human epididymis protein 4 levels to predict high-risk features in clinical stage 1 postmenopausal endometrial cancer patients. CA125: Cancer antigen 125; HE4: Human epididymis protein 4.

Open in New Tab Full Size Figure Download Figure

Figure 2 Disease-free survival in endometrial cancer patients with cancer antigen 125 < 20 U/mL and human epididymis protein 4 < 113 pmol/L compared with patients with cancer antigen 125 ≥ 20 U/mL and/or human epididymis protein 4 ≥ 113 pmol/L. CA125: Cancer antigen 125; HE4: Human epididymis protein 4.

Citation: Panyavaranant P, Manchana T. Preoperative markers for the prediction of high-risk features in endometrial cancer. World J Clin Oncol 2020; 11(6): 378-388
URL: https://www.wjgnet.com/2218-4333/full/v11/i6/378.htm
DOI: https://dx.doi.org/10.5306/wjco.v11.i6.378